

What is Daytrana? Learn about this ADHD patch, its uses, dosage, side effects, cost, and availability status in 2026. Everything patients need to know.
Daytrana is a prescription transdermal patch that delivers methylphenidate through the skin to treat Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6-17. It is the only ADHD medication that comes in a patch form, offering a non-oral alternative for patients who have difficulty swallowing pills or who benefit from the flexible dosing a patch allows.
Daytrana is classified as a Schedule II controlled substance due to its potential for abuse and dependence. It was manufactured by Noven Pharmaceuticals, a subsidiary of Hisamitsu Pharmaceutical.
Important update: Daytrana has been discontinued by its manufacturer and is no longer being produced. No generic version was ever approved. This article provides comprehensive information for patients researching the medication or seeking alternatives.
Daytrana is FDA-approved to treat ADHD in patients aged 6-17. ADHD is a neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with daily functioning and development.
Daytrana works by blocking the reuptake of dopamine and norepinephrine in the brain, increasing the availability of these neurotransmitters in the synaptic cleft. This helps improve focus, attention, and impulse control.
While not FDA-approved for these uses, some providers have prescribed methylphenidate (including Daytrana) off-label for:
These off-label uses were uncommon with Daytrana specifically, since oral methylphenidate formulations were more readily available and typically preferred for adults.
Daytrana is applied as a transdermal patch to the hip area. Here's how it works:
One unique advantage of Daytrana is that the duration of effect can be partially controlled by how long you wear the patch. Wearing it for a shorter period means a shorter duration of effect, which can help manage side effects like insomnia.
Daytrana was available in four strengths:
Doctors typically start with the lowest dose (10 mg/9 hr) and increase weekly based on response and tolerability.
Daytrana is not appropriate for everyone. The following are contraindications:
Patients with the following conditions should discuss risks carefully with their doctor:
For a full list of potential drug interactions, see our dedicated guide.
When it was available, Daytrana was one of the more expensive ADHD medications:
Noven Pharmaceuticals previously offered a savings card that reduced copays to as low as $25/month, but this program is no longer active since the medication was discontinued.
For current patients still finding Daytrana or looking at alternatives, our guide on saving money on Daytrana covers available options.
Daytrana has been discontinued by Noven Pharmaceuticals. The medication experienced supply disruptions starting around 2016-2017, and by 2023-2024 it became extremely difficult to find. No generic methylphenidate transdermal patch has been approved.
If you're looking for Daytrana or an available alternative:
Daytrana was a unique ADHD treatment that offered something no other medication could: transdermal delivery of methylphenidate via a daily patch. Its flexible dosing, non-oral format, and steady medication delivery made it a valuable option for many families.
While its discontinuation is a loss for patients who relied on it, the good news is that several effective ADHD treatments remain available. If you need help finding a medication, Medfinder can help you check real-time pharmacy availability near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.